Biomatter designs and delivers novel, custom enzymes for companies in health and sustainable manufacturing using an AI-first platform.

Founders

• Laurynas Karpus · CEO and co-founder
  He met Vykintas Jauniškis and Irmantas Rokaitis at Vilnius University's Institute of Biotechnology, where they first explored AI-driven enzyme generation.
• Vykintas Jauniškis · co-founder
  He met Laurynas Karpus and Irmantas Rokaitis at Vilnius University's Institute of Biotechnology, where they first explored AI-driven enzyme generation.
• Irmantas Rokaitis · co-founder
  He met Laurynas Karpus and Vykintas Jauniškis at Vilnius University's Institute of Biotechnology, where they first explored AI-driven enzyme generation.
• Donatas Repečka · co-founder
• Rolandas Meškys · co-founder
  He is identified as a professor at Vilnius University.

Business model

Biomatter makes money through partnership projects for enzyme development, optimization, production and scale-up, using flexible or outcome-based pricing alongside IP licensing and strategic collaboration.

Customers

AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi, Tereos, Thermo Fisher Scientific